Pfizer will receive a total of approximately 2.66 billion British pounds (about 3.56 billion US dollars) from selling Haleon's stocks and the share buyback of Haleon's stocks. Goldman Sachs International stated on Tuesday that Pfizer sold 0.64 billion ordinary shares of Haleon's consumer medical business in the United Kingdom at a price of 380 pence per share. The selling price was at a discount of 3.3% from Haleon's Monday closing price of 392.90 pence. Goldman Sachs also mentioned that in addition to issuing shares, Haleon agreed on Monday to repurchase approximately 60.5 million shares from Pfizer through off-exchange transactions at the same price, with a total value of around 0.23 billion British pounds. After the transaction is completed, Pfizer's stake in Haleon will decrease from about 22.6% to around 15%.
辉瑞将从出售Haleon的股票和Haleon的股票回购中获得约26.6亿英镑
Pfizer will receive approximately 2.66 billion British pounds from the sale of Haleon's stocks and the share buyback of Haleon's stocks.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.